NO20006544L - C-terminalt modifiserte oksamyldipeptider som inhibitorer av ICE/ced-3 familien av cystein proteaser - Google Patents

C-terminalt modifiserte oksamyldipeptider som inhibitorer av ICE/ced-3 familien av cystein proteaser

Info

Publication number
NO20006544L
NO20006544L NO20006544A NO20006544A NO20006544L NO 20006544 L NO20006544 L NO 20006544L NO 20006544 A NO20006544 A NO 20006544A NO 20006544 A NO20006544 A NO 20006544A NO 20006544 L NO20006544 L NO 20006544L
Authority
NO
Norway
Prior art keywords
ced
ice
family
inhibitors
cysteine proteases
Prior art date
Application number
NO20006544A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006544D0 (no
Inventor
Donald S Karanewsky
Robert J Ternansky
Original Assignee
Idun Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26784233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006544(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idun Pharmaceuticals Inc filed Critical Idun Pharmaceuticals Inc
Publication of NO20006544D0 publication Critical patent/NO20006544D0/no
Publication of NO20006544L publication Critical patent/NO20006544L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3264—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20006544A 1998-07-02 2000-12-21 C-terminalt modifiserte oksamyldipeptider som inhibitorer av ICE/ced-3 familien av cystein proteaser NO20006544L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9168998P 1998-07-02 1998-07-02
US09/177,549 US6197750B1 (en) 1998-07-02 1998-10-22 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
PCT/US1999/015074 WO2000001666A1 (en) 1998-07-02 1999-07-01 C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES

Publications (2)

Publication Number Publication Date
NO20006544D0 NO20006544D0 (no) 2000-12-21
NO20006544L true NO20006544L (no) 2001-02-28

Family

ID=26784233

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006544A NO20006544L (no) 1998-07-02 2000-12-21 C-terminalt modifiserte oksamyldipeptider som inhibitorer av ICE/ced-3 familien av cystein proteaser

Country Status (23)

Country Link
US (1) US6197750B1 (ko)
EP (2) EP1091930B1 (ko)
JP (1) JP3815968B2 (ko)
KR (1) KR100804432B1 (ko)
CN (1) CN1159289C (ko)
AT (2) ATE348096T1 (ko)
AU (1) AU752339B2 (ko)
BR (1) BR9911675A (ko)
CA (1) CA2336474C (ko)
CY (1) CY1108088T1 (ko)
DE (2) DE69941440D1 (ko)
DK (2) DK1091930T3 (ko)
ES (2) ES2330663T3 (ko)
HK (1) HK1036616A1 (ko)
HU (1) HUP0102898A3 (ko)
ID (1) ID28263A (ko)
IL (1) IL140554A0 (ko)
MX (1) MXPA00013014A (ko)
NO (1) NO20006544L (ko)
NZ (1) NZ509025A (ko)
PL (1) PL207578B1 (ko)
PT (1) PT1091930E (ko)
WO (1) WO2000001666A1 (ko)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1647279A3 (en) * 1996-09-12 2006-04-26 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
BR9909660A (pt) * 1998-03-19 2000-11-21 Vertex Pharma Inibidores de caspases
US7053056B2 (en) * 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
ATE363465T1 (de) 1999-04-09 2007-06-15 Cytovia Inc Caspase inhibitoren und ihre verwendung
DE60040397D1 (de) 1999-08-27 2008-11-13 Cytovia Inc Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung
KR20020058078A (ko) 1999-12-03 2002-07-12 우에노 도시오 옥사디아졸 유도체 및 그 유도체를 유효 성분으로 하는 약제
US6790989B2 (en) * 2000-01-13 2004-09-14 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
US6515173B1 (en) * 2000-01-13 2003-02-04 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
WO2001079162A2 (en) * 2000-04-17 2001-10-25 Idun Pharmaceuticals, Inc. INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002245649A1 (en) * 2001-03-02 2002-09-19 Idun Pharmaceuticals, Inc. Methods, compositions and kits for preserving antigenicity
WO2003062192A1 (en) 2002-01-17 2003-07-31 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
WO2003068242A1 (en) * 2002-02-11 2003-08-21 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
EP1499898A2 (en) * 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
CA2500196A1 (en) * 2002-09-25 2004-04-08 University Of Rochester Caspase inhibitors as anticancer agents
US7923433B2 (en) 2002-10-09 2011-04-12 Activx Biosciences, Inc. Activity-based probes and methods of their preparation and use
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
AU2004290413A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring IL-18
WO2005090334A2 (en) 2004-03-12 2005-09-29 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
US7531570B2 (en) * 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
KR20070086610A (ko) 2004-11-24 2007-08-27 버텍스 파마슈티칼스 인코포레이티드 3-[2-(3-아실아미노-2-옥소-2ｈ-피리딘-1-일)-아세틸아미노]-4-옥소-펜탄산 유도체 및 카스파제 억제제로서의 이의용도
US20090214527A1 (en) * 2005-07-11 2009-08-27 Gary Burgess Combination Of Anti-Madcam Antibody And Antifibrotic Caspase Inhibitor To Treat Liver Fibrosis
CN101268084A (zh) * 2005-07-28 2008-09-17 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物
PT2091910E (pt) * 2006-12-06 2014-11-18 Conatus Pharmaceuticals Inc Formas cristalinas do ácido (3s)-3-[n-(n¿-(2-tercbutilfenil) oxamil)alaninil]amino-5-(2¿,3¿,5¿,6¿- tetrafluorofenoxi)-4-oxopentanóico
WO2012061785A2 (en) 2010-11-05 2012-05-10 Brandeis University Ice inhibiting compounds and uses thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
EP4218829A3 (en) 2013-03-15 2023-08-16 The Board of Trustees of the Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
EP3142649B1 (en) 2014-05-12 2019-07-24 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitor emricasan
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
SG11201805480TA (en) 2015-12-31 2018-07-30 Conatus Pharmaceuticals Inc Methods of using caspase inhibitors in treatment of liver disease
MX2019003889A (es) 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
AU2017382460A1 (en) 2016-12-23 2019-05-02 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
CA3050832A1 (en) * 2017-01-23 2018-07-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compounds as a capase inhibitor
WO2019174589A1 (zh) * 2018-03-13 2019-09-19 正大天晴药业集团股份有限公司 一种Caspase抑制剂的结晶
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
EP0618223A3 (en) 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
TW494094B (en) * 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

Also Published As

Publication number Publication date
ES2276520T3 (es) 2007-06-16
ATE442843T1 (de) 2009-10-15
ID28263A (id) 2001-05-10
EP1091930A1 (en) 2001-04-18
EP1754475B1 (en) 2009-09-16
DE69941440D1 (de) 2009-10-29
DE69934405T2 (de) 2007-10-31
CN1313846A (zh) 2001-09-19
HK1036616A1 (en) 2002-01-11
DK1091930T3 (da) 2007-04-02
NZ509025A (en) 2003-05-30
EP1091930B1 (en) 2006-12-13
PT1091930E (pt) 2007-02-28
NO20006544D0 (no) 2000-12-21
BR9911675A (pt) 2002-02-05
JP2002519406A (ja) 2002-07-02
AU4856999A (en) 2000-01-24
WO2000001666A1 (en) 2000-01-13
KR20010083079A (ko) 2001-08-31
IL140554A0 (en) 2002-02-10
MXPA00013014A (es) 2004-04-02
HUP0102898A2 (hu) 2002-01-28
EP1754475A1 (en) 2007-02-21
CA2336474A1 (en) 2000-01-13
PL345350A1 (en) 2001-12-17
PL207578B1 (pl) 2011-01-31
CA2336474C (en) 2008-04-29
US6197750B1 (en) 2001-03-06
CY1108088T1 (el) 2014-02-12
DK1754475T3 (da) 2009-11-09
ES2330663T3 (es) 2009-12-14
CN1159289C (zh) 2004-07-28
HUP0102898A3 (en) 2002-09-30
JP3815968B2 (ja) 2006-08-30
DE69934405D1 (de) 2007-01-25
KR100804432B1 (ko) 2008-02-20
AU752339B2 (en) 2002-09-19
ATE348096T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
NO20006544L (no) C-terminalt modifiserte oksamyldipeptider som inhibitorer av ICE/ced-3 familien av cystein proteaser
NO20011968L (no) (Substituerte)acyl dipeptidyl-inhibitorer av ICE/ced-3 familien av cysteinproteaser
WO2003072528A3 (en) (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
Li et al. Peptide. alpha.-keto ester,. alpha.-keto amide, and. alpha.-keto acid inhibitors of calpains and other cysteine proteases
IL122116A0 (en) Polypeptide comprising kunitz-type serine protease inhibitor
MX9804262A (es) Inhibidores derivados de d-aminoacidos de proteasas de cisteina y serina.
NO990548L (no) Inhibitorer for cystein-protease
MY119155A (en) New peptide derivatives
PT739355E (pt) Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
ZA959819B (en) Substituted heterocylic compounds useful as inhibitors of (serine protease) human neutrophil elastase
NZ513885A (en) C-terminal modified (N-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
WO2002057298A3 (en) C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
EA200100804A1 (ru) Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз
HK1016495A1 (en) Phosphorous-containing cysteine and serine protease inhibitors
NO971444D0 (no) Inhibitor av stamcelle-proliferasjon og anvendelser derav
HK1029936A1 (en) Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors
ATE229973T1 (de) C-terminale modifizierte (n-substituierte)-2- indolyl dipeptide als inhibitoren von der ice/ced-3 cysteinprotease familie
AU4583597A (en) Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes
WO2001034565A3 (en) Protease inhibitors
WO2001049309A3 (en) Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue
AU2001252419A1 (en) Thrombin inhibitors
WO2001079162A3 (en) INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
WO2002011750A3 (en) Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
DK0651764T3 (da) Cytotoksisk T-lymfocytantigen som cysteinproteaseinhibitor
Iqbal et al. Proteasome inhibitors